850 related articles for article (PubMed ID: 22303521)
1. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
2. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.
Schaffer A; McIntosh D; Goldstein BI; Rector NA; McIntyre RS; Beaulieu S; Swinson R; Yatham LN;
Ann Clin Psychiatry; 2012 Feb; 24(1):6-22. PubMed ID: 22303519
[TBL] [Abstract][Full Text] [Related]
3. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.
McIntyre RS; Alsuwaidan M; Goldstein BI; Taylor VH; Schaffer A; Beaulieu S; Kemp DE;
Ann Clin Psychiatry; 2012 Feb; 24(1):69-81. PubMed ID: 22303523
[TBL] [Abstract][Full Text] [Related]
4. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
[TBL] [Abstract][Full Text] [Related]
5. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder.
Tourjman SV; Buck G; Jutras-Aswad D; Khullar A; McInerney S; Saraf G; Pinto JV; Potvin S; Poulin MJ; Frey BN; Kennedy SH; Lam RW; MacQueen G; Milev R; Parikh SV; Ravindran A; McIntyre RS; Schaffer A; Taylor VH; van Ameringen M; Yatham LN; Beaulieu S
Can J Psychiatry; 2023 May; 68(5):299-311. PubMed ID: 35711159
[TBL] [Abstract][Full Text] [Related]
6. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders.
Rosenbluth M; Macqueen G; McIntyre RS; Beaulieu S; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):56-68. PubMed ID: 22303522
[TBL] [Abstract][Full Text] [Related]
7. Current status of co-occurring mood and substance use disorders: a new therapeutic target.
Pettinati HM; O'Brien CP; Dundon WD
Am J Psychiatry; 2013 Jan; 170(1):23-30. PubMed ID: 23223834
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis.
Hunt GE; Malhi GS; Cleary M; Lai HM; Sitharthan T
J Affect Disord; 2016 Dec; 206():331-349. PubMed ID: 27476137
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
[TBL] [Abstract][Full Text] [Related]
10. Polysubstance Use, Mood Disorders, and Chronic Conditions With Anxiety in Opioid Patients.
Liu S; Nwabueze C; Pan Y; Walter SM; Su B; Xu C; Winstanley EL; Wang K
West J Nurs Res; 2022 Dec; 44(12):1088-1099. PubMed ID: 34301163
[TBL] [Abstract][Full Text] [Related]
11. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Yatham LN; Kennedy SH; O'Donovan C; Parikh S; MacQueen G; McIntyre R; Sharma V; Silverstone P; Alda M; Baruch P; Beaulieu S; Daigneault A; Milev R; Young LT; Ravindran A; Schaffer A; Connolly M; Gorman CP;
Bipolar Disord; 2005; 7 Suppl 3():5-69. PubMed ID: 15952957
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: Systematic review and meta-analysis.
Hunt GE; Malhi GS; Cleary M; Lai HM; Sitharthan T
J Affect Disord; 2016 Dec; 206():321-330. PubMed ID: 27426694
[TBL] [Abstract][Full Text] [Related]
13. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
Malhi GS; Bassett D; Boyce P; Bryant R; Fitzgerald PB; Fritz K; Hopwood M; Lyndon B; Mulder R; Murray G; Porter R; Singh AB
Aust N Z J Psychiatry; 2015 Dec; 49(12):1087-206. PubMed ID: 26643054
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of depressive and bipolar disorder patients with mixed features.
Tondo L; Vázquez GH; Pinna M; Vaccotto PA; Baldessarini RJ
Acta Psychiatr Scand; 2018 Sep; 138(3):243-252. PubMed ID: 29862493
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up.
Mazza M; Mandelli L; Di Nicola M; Harnic D; Catalano V; Tedeschi D; Martinotti G; Colombo R; Bria P; Serretti A; Janiri L
J Affect Disord; 2009 May; 115(1-2):27-35. PubMed ID: 18845344
[TBL] [Abstract][Full Text] [Related]
16. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Yatham LN; Kennedy SH; O'Donovan C; Parikh SV; MacQueen G; McIntyre RS; Sharma V; Beaulieu S;
Bipolar Disord; 2006 Dec; 8(6):721-39. PubMed ID: 17156158
[TBL] [Abstract][Full Text] [Related]
17. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder.
McIntyre RS; Rosenbluth M; Ramasubbu R; Bond DJ; Taylor VH; Beaulieu S; Schaffer A;
Ann Clin Psychiatry; 2012 May; 24(2):163-9. PubMed ID: 22563572
[TBL] [Abstract][Full Text] [Related]
18. Substance use disorders comorbid with mood and anxiety disorders in the Australian general population.
Prior K; Mills K; Ross J; Teesson M
Drug Alcohol Rev; 2017 May; 36(3):317-324. PubMed ID: 27324816
[TBL] [Abstract][Full Text] [Related]
19. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
20. Substance use comorbidity in bipolar disorder: A qualitative review of treatment strategies and outcomes.
Gold AK; Otto MW; Deckersbach T; Sylvia LG; Nierenberg AA; Kinrys G
Am J Addict; 2018 Apr; 27(3):188-201. PubMed ID: 29596721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
